Filing Details

Accession Number:
0000899243-22-033325
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2022-10-07 20:19:53
Reporting Period:
2021-11-17
Accepted Time:
2022-10-07 20:19:53
Original Submission Date:
2022-10-04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1830214 Ginkgo Bioworks Holdings Inc. DNA Biological Products, (No Disgnostic Substances) (2836) 872652913
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1883686 E. Marie Fallon C/O Ginkgo Bioworks Holdings, Inc.
27 Drydock Avenue
Boston MA 02210
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2022-09-30 6,134 $0.00 6,134 No 4 M Direct
Class A Common Stock Acquisiton 2022-10-01 226,376 $0.00 232,510 No 4 M Direct
Class A Common Stock Disposition 2022-10-03 2,722 $3.12 229,788 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class A Common Stock Class B Common Stock Disposition 2022-09-30 6,134 $0.00 0 $0.00
Class A Common Stock Restricted Stock Units Acquisiton 2021-11-17 490,805 $0.00 0 $0.00
Class A Common Stock Restricted Stock Units Disposition 2022-10-01 226,376 $0.00 0 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
52,760 No 4 M Direct
680,805 No 4 A Direct
442,161 No 4 M Direct
Footnotes
  1. Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.
  2. Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.
  3. Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 226,376 of the RSUs was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.
  4. Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction.
  5. Includes shares of Class B Common Stock that are subject to vesting conditions. Excludes RSUs, which were previously reported as shares of Class B Common Stock on the Form 4 filed by the reporting person on March 14, 2022. Because the Issuer has the ability to settle such RSUs with shares of Class A Common Stock or cash upon vesting, RSUs will be reported separately from shares of Class B Common Stock in future reports.
  6. Includes RSUs that are subject to vesting conditions. Includes 190,000 RSUs that were acquired after November 17, 2021.